All In Biotech

Drug Trial Radar · NCT05163847

Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults

Phase 1b Study to Investigate the Safety and Immunogenicity of Cam2020 (A/Cambodia/e0826360/2020) M2SR H3N2 Monovalent Influenza Vaccine Administered Alone or With Licensed, Inactivated Influenza Vaccine in Adults 65 to 85 Years Old

Last checked: Nov 19, 2026Latest source record: Nov 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 303 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

303

Actual

Start

Jun 14, 2022

Primary completion

Nov 3, 2022

Study completion Nov 3, 2022

Sponsor

Lead sponsor
FluGen IncIndustry
Sponsor type
Industry
Collaborators
United States Department of Defense
First posted
Dec 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 65 years, up to 85 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, double-dummy, placebo-controlled Phase 1b study evaluating the safety and immunogenicity of the investigational Cam2020 M2SR H3N2 influenza vaccine delivered IN alone or concomitantly with inactivated influenza vaccine (IIV) delivered IM to a healthy adult population age 65 to 85 years at time of enrollment.

Conditions

  • Influenza Vaccine

Interventions

  • Cam2020 M2SR H3N2 influenza vaccineBiological

    Administered intranasally on Day 1

  • Fluzone HD IIVBiological

    Administered intramuscularly on Day 1

  • IN PlaceboOther

    Administered intranasally on Day 1

  • IM PlaceboOther

    Administered intramuscularly on Day 1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Solicited AEs during 7 days after experimental treatmentTime frame: Day 1 to Day 8
  2. Unsolicited AEs during 28 days after experimental treatmentTime frame: Day 1 to Day 29
  3. SAEs through 28 days after experimental treatmentTime frame: Day 1 to Day 29

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • United Medical Research

    Port Orange, Florida

  • Velocity Clinical Research

    Meridian, Idaho

  • Johnson County Clin Trials

    Lenexa, Kansas

  • Rochester Clinical Research

    Rochester, New York

  • Velocity Clinical Research

    Beechwood, Ohio

  • Velocity Clinical Research

    Cedar Park, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.